Cover Image

Virometix AG的產品平台分析

Virometix AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 274680
出版日期 內容資訊 英文 18 Pages
Back to Top
Virometix AG的產品平台分析 Virometix AG - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 18 Pages



Virometix AG是總公司設立於瑞士的生物科技企業,從事感染疾病和慢性疾病治療及預防用新一代疫苗·免疫治療藥的藥物研發·開發。該公司利用,免疫系統上抗原遞輸及免疫細胞活性化所需的類病毒顆粒合成(SVLP)技術,與抗原的設計及優化所需的抗原模仿物質之合成(SAM)技術,進行肺炎球菌疫苗及癌症疫苗的開發。

本報告提供Virometix AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。


Virometix AG 基本資料

  • Virometix AG 概要
  • 主要資訊
  • 企業資料

Virometix AG :R&D概要

  • 主要的治療範圍

Virometix AG :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Virometix AG :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Virometix AG :藥物簡介

  • Vaccines for HPV Associated Cervical Cancer
  • pneumococcal vaccine
  • RSV vaccine
  • Vaccines for Oncology

Virometix AG :開發平台分析

  • 各分子類型

Virometix AG :開發暫停中的計劃

Virometix AG :總公司和子公司的所在地

  • 總公司



Product Code: GMDHC07393CDB


Global Markets Direct's, 'Virometix AG - Product Pipeline Review - 2015', provides an overview of the Virometix AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Virometix AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Virometix AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Virometix AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Virometix AG's pipeline products

Reasons to buy

  • Evaluate Virometix AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Virometix AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Virometix AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Virometix AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Virometix AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Virometix AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Virometix AG Snapshot
    • Virometix AG Overview
    • Key Information
    • Key Facts
  • Virometix AG - Research and Development Overview
    • Key Therapeutic Areas
  • Virometix AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Virometix AG - Pipeline Products Glance
    • Virometix AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Virometix AG - Drug Profiles
    • pneumococcal virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RSV virus like particle vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccines for HPV Associated Cervical Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccines for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Virometix AG - Pipeline Analysis
  • Virometix AG - Pipeline Products by Molecule Type
  • Virometix AG - Dormant Projects
  • Virometix AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Virometix AG, Key Information
  • Virometix AG, Key Facts
  • Virometix AG - Pipeline by Indication, 2015
  • Virometix AG - Pipeline by Stage of Development, 2015
  • Virometix AG - Monotherapy Products in Pipeline, 2015
  • Virometix AG - Preclinical, 2015
  • Virometix AG - Pipeline by Molecule Type, 2015
  • Virometix AG - Dormant Developmental Projects,2015

List of Figures

  • Virometix AG - Pipeline by Top 10 Indication, 2015
Back to Top